GenoMed has discovered and applied for patent protection on a treatment that could have wide-ranging use for over 150 common diseases that currently carry a dismal prognosis. These include diabetes and its complications (which affects 20 million in the United States alone), high blood pressure and its complications (which affects 60 million in the U.S.); emphysema and other smoking-related diseases; and many other serious diseases, including infection with HIV and progression to AIDS, common solid cancers such as lung, colon, pancreas, liver, and kidney; cancers of the blood-stream such as chronic leukemias, multiple myeloma, and lymphomas; and immune-mediated diseases such as multiple sclerosis, degenerative joint disease (osteoarthritis) and rheumatoid arthritis.
GenoMed has found that over-activity of a single enzyme, angiotensin I-converting enzyme (“ACE”), may be behind these diseases. The logical treatment is effective inhibition of the ACE enzyme, using the correct dose of the correct ACE inhibitor. As a class, ACE inhibitors have been in widespread use since the 1970’s, and have a very well-known safety profile. The company has so far had dramatically positive results in the following diseases:
1. Chronic kidney failure due to adult-onset diabetes.
Regression of disease was seen when GenoMed’s treatment was begun early, before a patient’s serum creatinine reaches 2 milligrams per deciliter. This means prevention of the need for kidney dialysis. This treatment has worked in both white and black men, and in Hispanic patients of both genders. Enough male patients have already been seen for statistical significance (see Moskowitz, “ACE Example”).
2. Chronic kidney failure due to high blood pressure.
Like diabetic kidney disease, prevention of dialysis was seen if the new treatment is begun early, before the serum creatinine, a measure of kidney failure, reaches 2 mg/dl. Diabetes and high blood pressure are responsible for 85% of dialysis in the United States, which currently costs $18 billion a year. Enough male patients have already been seen for statistical significance (see Moskowitz, “ACE Example”).
3. Poor circulation due to high blood pressure.
In 2 men who smoked, one black and one white, surgery to revascularize the leg was delayed for 4 to 5 years (see Moskowitz, “ACE Example”).
4. End-stage emphysema.
In one white man who continued to smoke, death from end-stage emphysema was delayed by 7 years and one month (see Moskowitz, “ACE Example”).
One white man taking methotrexate for his psoriasis was able to discontinue methotrexate after several weeks of starting GenoMed’s treatment (unpublished case report).
GenoMed has found close to 160 common diseases which it predicts should respond to its patent-pending approach (see Moskowitz, “Master Disease Gene”). All of these diseases are acquired as one ages. If GenoMed’s proprietary treatment can dramatically delay or even prevent these diseases, then GenoMed’s treatment could justifiably be called at least a component of the Fountain of Youth. The more diseases which respond to this treatment, the more appropriate will be the name “Fountain of Youth” itself for GenoMed’s approach. Only time and further clinical experience will tell.
GenoMed is anxious to enroll many more patients with common diseases in our Clinical Outcomes Improvement Program™.